(Q34593792)

English

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

therapeutic vaccine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

immunologic adjuvant

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Bernard Escudier

15

object named as

Bernard Escudier

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Peter F.A. Mulders

7

object named as

Peter Mulders

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Christopher Wood

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Pramod Srivastava

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ronald Bukowski

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Louis Lacombe

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Andrei I Gorelov

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sergei Gorelov

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Henryk Zielinski

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Axel Hoos

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Florentina Teofilovici

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Leah Isakov

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Robert Flanigan

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Robert Figlin

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Renu Gupta

14

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

C-100-12 RCC Study Group

16

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

3 July 2008

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

372

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

9633

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

145-154

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of lymphadenectomy in the treatment of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Staging of renal cell carcinoma: current concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved prognostication of renal cell carcinoma using an integrated staging system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Purification of the heat shock protein, gp96, from natural sources

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The challenges of bringing autologous HSP-based vaccines to commercial reality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Testing for qualitative interactions between treatment effects and patient subsets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960697-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(08)60697-2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34593792&oldid=2257729627"